韓國藥品市場 是由出版商Espicom Business Intelligence在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 64 價格從美金1085起跳。
韓國藥品市場在2008年達到120億美元的規模，平均每人支出金額為244美元。預計該市場今後將維持5.0％左右的成長率，在2013年之前達到156億美元，平均每人消費312美元的規模。
本報告書內容包括：韓國藥品市場分析、未來5年內的市場預測及進出口等統計資料、未來市場預測、法規限制動向等。內容綱要摘記如下：
市場預測
藥品市場分析
- 現在的市場規模
- 市場結構
- 5年內預測
- 進口
- 國内製造
- 出口
- 研究開發
藥品相關法規限制分析
藥品銷售
醫療分析
醫療資料
- 經濟指標
- 人口統計
- 醫療費用
- 醫院及基礎照護資料
- 醫療從業人員
Abstract
Politically, South Korea is entrenched in parliamentary disagreements between
the two main parties and the situation with North Korea is constantly
changing. Economically, South Korea's GDP is projected to become the fourth
largest economy in the Asia Pacific region by 2016. Legally, South Korea still
has problems with regards to data exclusivity, failure of multinational
companies to maintain patent protection and the issue of legal courts
favouring domestic companies and branded generic production. Demographically,
South Korea has a fairly large population, which is over double the size of
Australia or Taiwan. Although compared to many Western countries the
population is not old, the elderly population is growing.
The implementation of the EU-Korea Free Trade Agreement (FTA) will provide EU
companies with better access to the South Korean pharmaceutical market
by paving the way for elimination of tariffs on EU pharmaceutical exports to
the country. The volume and value of EU pharmaceutical exports are expected to
increase with the implementation of EU-Korea FTA, posing a potential threat to
US pharmaceutical exporters. The EU-Korea FTA also stipulates that South
Korean authorities will be required to align their practices with
international standards through an improved regulatory environment. In
particular, the EU-Korea FTA will aim to ensure the strengthening of
transparency in drug pricing decisions, as there have been concerns about the
lack of transparency in the South Korean health authorities' price setting.
The biologic sector in South Korea is witnessing rapid growth. In the
first half of 2011, a number of competitive strategies have been completed.
Celltrion signed an agreement with Novacell Technology to develop biosimilars;
Dong-A and POSTECH signed a MoU for co-operation on new biotechnology-based
drugs; Il-Yang opened its new influenza vaccine plant in Eumseong, Chungcheon
province; Korea Green Cross reported that its seasonal flu vaccine, GC Flu,
had obtained WHO prequalification; Daewoong and Binex signed an agreement to
jointly develop a biosimilar of Enbrel (etanercept); and Korea Green Cross and
TEPIK announced a collaboration to develop and commercialise a cell culture
influenza vaccine.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been
redesigned to provide enhanced strategic intelligence in a user-friendly
format. Each report provides in-depth information, setting the pharmaceutical
market in context.
The reports provide:
- Five-year projections for economic, demographic, health expenditure,
health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence
Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health
infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest
information for a full year. In addition, the service will keep you up to date
with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health
expenditure, hospital and primary care infrastructure & services and
healthcare personnel, is additionally included.
Report Statistics
- Publication Date: October 31st 2011
- Total Number of Pages: 64
- Formats: Web, PDF and Paper
Table of Contents
EXECUTIVE SUMMARY
- Snapshot: Strategic Espicom Analysis
- Snapshot: Key Data Projections
MACROENVIRONMENT
- POLITICAL
- ECONOMIC
- LEGAL
- DEMOGRAPHIC
- Projections
- Latest Figures
- Demographic Indicators
- Births
- Deaths
- Life Expectancy at Birth
EPIDEMIOLOGY
- DISEASE BURDEN
- DISEASE PREVALENCE
- Communicable Diseases
- Non-communicable Diseases
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS
- ORGANISATION
- Healthcare Funding
- Medical Tourism
- Medical Tourism Complex in Jeju
- Spending by Medical Tourists Rises
- Medical Tourism Marketing Legalised
- EXPENDITURE
- INFRASTRUCTURE
- Hospital Infrastructure
- Outpatient Infrastructure
- SERVICES
- Inpatient Analysis
- Outpatient Analysis
- WORKFORCE
- Projections
- Latest Figures
REGULATORY AFFAIRS
- NATIONAL AUTHORITIES
- Pharmaceutical Affairs Bureau
- Korean Food & Drug Administration
- Central Pharmaceutical Affairs Council
- PHARMACEUTICAL AFFAIRS LAW
- KOREAN PHARMACOPOEIA
- OTHER SPECIFICATION STANDARDS
- OTHER REGULATIONS
- Good Laboratory Practice
- Good Clinical Practice
- Good Manufacturing Practice
- REGULATORY DEVELOPMENTS
- RFID Plan
- Semi-finished Product Testing
- MARKETING REGISTRATION
- Product Registration
- Clinical Trials
- POST-MARKETING SURVEILLANCE
- Re-examination Reports
- Adverse Drug Reactions
- PROMOTION
PRICING & REIMBURSEMENT
- Pricing & Reimbursement Developments
- Preferential Drug Price-Cut Exemption Policy
- Transacted Drug Price Control System
DISTRIBUTION CHANNELS
- Prescriber/Dispenser Split
- DRUG WHOLESALING
- Trade Associations
- Selected Wholesaler
MARKET ANALYSIS
- SIZE
- Projections
- Historical Figures
- PRODUCT DEVELOPMENT
- Government R&D Grants
- Partial Exemption from Drug Price Reductions for High Cost R&D
Pharmaceutical Companies
- Pfizer's Research Partnership with Samsung Medical Centre
- MANUFACTURING
- TRADE
- Exports
- Imports
- Balance of Trade
COMPETITION
- TRADE ASSOCIATIONS
- COMPANY INTELLIGENCE
- Domestic Manufacturers
- Ahngook
- Binex
- Bukwang
- Dong-A
- Dong Wha
- Handok
- Huons
- Hyundai
- Ildong
- Kuhnil
- WhanIn
- Yooyoung
- Yuhan
- Multinational Manufacturers
- Competitive Strategies
OTC PHARMACEUTICALS
- REGULATION
- MARKET SIZE
- COMPETITION
GENERIC PHARMACEUTICALS
- REGULATION
- MARKET SIZE
- COMPETITION
- Company Intelligence
- Chong Kun Dang
- Choongwae
- Daewoong
- Hanmi
- Competitive Strategies
BIOLOGICS & BIOSIMILARS
- REGULATION
- MARKET SIZE
- PRODUCT DEVELOPMENT
- COMPETITION
- Trade Fair
- Company Intelligence
- Celltrion
- CJ
- CKD Bio
- CrystalGenomics
- Dong-A
- Histostem
- Il-Yang
- ISU ABXIS
- Genexine
- KAEL-GemVax
- Korea Green Cross
- LGLS
- Medy-Tox
- RNL Bio
- Seoul
- SK Chemicals
- Competitive Strategies
CONCLUSIONS: OPPORTUNITIES & CHALLENGES
- Strategic Espicom Analysis
- MACROENVIRONMENT
- EPIDEMIOLOGY
- HEALTHCARE
- REGULATORY AFFAIRS
- PRICING & REIMBURSEMENT
- DISTRIBUTION CHANNELS
- MARKET
- COMPETITION
- OTC PHARMACEUTICALS
- GENERIC PHARMACEUTICALS
- BIOLOGICS & BIOSIMILARS
- Radar Analysis
- SWOT Analysis
DIRECTORY
- GOVERNMENT ORGANISATIONS
- PHARMACEUTICAL COMPANIES
- TRADE ORGANISATIONS
LIST OF TABLES
- Espicom Analysis of the Pharmaceutical Market, 2011
- Key Data Projections, 2011-2016
- Political Landscape, 2011
- Regional Ranking of Projected Economies, 2016
- Projected Economy, 2011-2016
- Regional Ranking of Projected Demographics, 2016
- Projected Demographics, 2011-2016
- Demographic Indicators, 2004-2010
- Leading Causes of Death, 2008 (000s)
- Regional Ranking of Projected Health Expenditure, 2016
- Projected Health Expenditure, 2011-2016
- Regional Ranking of Projected Physicians, 2016
- Projected Physicians, 2011-2016
- Pharmaceutical Distributors by Type, 2000-2008
- Pharmaceutical Wholesalers by Region, 2008
- Pharmaceutical Retailers by Region, 2008
- Regional Ranking of Projected Pharmaceutical Markets, 2016
- Projected Pharmaceutical Market at Retail Prices, 2011-2016
- Historical Pharmaceutical Market at Retail Prices, 1995-2010
- MOHW's R&D Grants by Company & Industry Field, 2004-2009
- Pharmaceutical Manufacturers by Type, 2004-2008
- Domestic Pharmaceutical Production, 1991-2009 (Million Won)
- Pharmaceutical Production by Type, 2008
- Pharmaceutical Exports by Category, 2006-2010 (US$000s)
- Pharmaceutical Exports by Country/Region, 2010 (US$000s)
- Pharmaceutical Imports by Category, 2006-2010 (US$000s)
- Imports of Raw Materials by Country/Region, 2010 (US$000s)
- Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s)
- Imports of Medicaments by Country/Region, 2010 (US$000s)
- Pharmaceutical Balance of Trade, 2006-2010 (US$000s)
- Companies with a Representative on KPMA Board of Directors, 2011
- KRPIA Members, 2011
- Biotechnology Industry Production, 2003-2009 (Billion Won)
- Espicom Analysis of the Pharmaceutical Market, 2011
- SWOT Analysis of the Pharmaceutical Market, 2011
LIST OF CHARTS
- Regional Comparison of Top 5 Projected Pharmaceutical Markets at Retail
Prices, 2016
- Regional Comparison of Projected Pharmaceutical Market Share, 2016
- Historical Pharmaceutical Market at Retail Prices, 1995-2010
- Pharmaceutical Exports, 2004-2010 (US$ Millions)
- Pharmaceutical Imports, 2004-2010 (US$ Billions)
- Pharmaceutical Imports by Country/Region, 2010 (%)
- Pharmaceutical Balance of Trade, 2004-2010 (US$ Billions)
- Radar Graph of the Pharmaceutical Market, 2011
|
